On the Path toward Classifying Hormones of the Vasoinhibin-Family.
作者信息
Triebel Jakob, Bertsch Thomas, Martínez de la Escalera Gonzalo, Clapp Carmen
机构信息
Institute for Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Paracelsus Medical University , Nuremberg , Germany.
Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Campus UNAM-Juriquilla , Querétaro , México.
出版信息
Front Endocrinol (Lausanne). 2015 Feb 10;6:16. doi: 10.3389/fendo.2015.00016. eCollection 2015.
Abstract
摘要
相似文献
1
On the Path toward Classifying Hormones of the Vasoinhibin-Family.迈向血管抑制素家族激素分类之路
Front Endocrinol (Lausanne). 2015 Feb 10;6:16. doi: 10.3389/fendo.2015.00016. eCollection 2015.
2
From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.从实验室到临床：催乳素/血管抑制素轴的转化
Front Endocrinol (Lausanne). 2017 Dec 11;8:342. doi: 10.3389/fendo.2017.00342. eCollection 2017.
3
Prolactin-derived vasoinhibins increase anxiety- and depression-related behaviors.催乳素衍生的血管抑制素会增加焦虑和抑郁相关的行为。
Psychoneuroendocrinology. 2014 Jun;44:123-32. doi: 10.1016/j.psyneuen.2014.03.006. Epub 2014 Mar 21.
4
Principles of the prolactin/vasoinhibin axis.催乳素/血管抑制素轴的原理。
Am J Physiol Regul Integr Comp Physiol. 2015 Nov 15;309(10):R1193-203. doi: 10.1152/ajpregu.00256.2015. Epub 2015 Aug 26.
5
Human Prolactin Point Mutations and Their Projected Effect on Vasoinhibin Generation and Vasoinhibin-Related Diseases.人类催乳素点突变及其对血管抑制素生成和血管抑制素相关疾病的预期影响。
Front Endocrinol (Lausanne). 2017 Nov 6;8:294. doi: 10.3389/fendo.2017.00294. eCollection 2017.
6
Cathepsin D is the primary protease for the generation of adenohypophyseal vasoinhibins: cleavage occurs within the prolactin secretory granules.组织蛋白酶 D 是腺垂体血管抑制素生成的主要蛋白酶：裂解发生在泌乳素分泌颗粒内。
Endocrinology. 2009 Dec;150(12):5446-54. doi: 10.1210/en.2009-0390. Epub 2009 Oct 9.
7
Commentary: Prolactin Alters Blood Pressure by Modulating the Activity of Endothelial Nitric Oxide Synthase.评论：催乳素通过调节内皮型一氧化氮合酶的活性来改变血压。
Front Endocrinol (Lausanne). 2017 May 22;8:105. doi: 10.3389/fendo.2017.00105. eCollection 2017.
8
A Dysregulation of the Prolactin/Vasoinhibin Axis Appears to Contribute to Preeclampsia.催乳素/血管抑制素轴的失调似乎与子痫前期有关。
Front Endocrinol (Lausanne). 2020 Jan 9;10:893. doi: 10.3389/fendo.2019.00893. eCollection 2019.
9
Vasoinhibins May Contribute to Postpartum Depression.血管抑制素可能与产后抑郁症有关。
Front Psychiatry. 2017 Sep 12;8:167. doi: 10.3389/fpsyt.2017.00167. eCollection 2017.
10
Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability.腺相关病毒 2 介导的血管抑素基因转移可防治 VEGF 和糖尿病引起的视网膜血管通透性增加。
Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8944-50. doi: 10.1167/iovs.11-8190.
引用本文的文献
1
The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis.14 千道尔顿人生长激素片段是一种有效的血管生成和肿瘤转移抑制剂。
Int J Mol Sci. 2023 May 17;24(10):8877. doi: 10.3390/ijms24108877.
2
Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited.催乳素和血管抑素是糖尿病视网膜病变的内源性参与者的再探讨。
Front Endocrinol (Lausanne). 2022 Sep 9;13:994898. doi: 10.3389/fendo.2022.994898. eCollection 2022.
3
Regulator of Angiogenesis and Vascular Function: A 2019 Update of the Vasoinhibin Nomenclature.血管生成与血管功能调节剂：2019年血管抑制素命名法更新
Front Endocrinol (Lausanne). 2019 Apr 10;10:214. doi: 10.3389/fendo.2019.00214. eCollection 2019.
4
From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.从实验室到临床：催乳素/血管抑制素轴的转化
Front Endocrinol (Lausanne). 2017 Dec 11;8:342. doi: 10.3389/fendo.2017.00342. eCollection 2017.
5
Human Prolactin Point Mutations and Their Projected Effect on Vasoinhibin Generation and Vasoinhibin-Related Diseases.人类催乳素点突变及其对血管抑制素生成和血管抑制素相关疾病的预期影响。
Front Endocrinol (Lausanne). 2017 Nov 6;8:294. doi: 10.3389/fendo.2017.00294. eCollection 2017.
6
Remarks on the Prolactin Hypothesis of Peripartum Cardiomyopathy.关于围产期心肌病催乳素假说的评论
Front Endocrinol (Lausanne). 2017 Apr 11;8:77. doi: 10.3389/fendo.2017.00077. eCollection 2017.
7
Principles of the prolactin/vasoinhibin axis.催乳素/血管抑制素轴的原理。
Am J Physiol Regul Integr Comp Physiol. 2015 Nov 15;309(10):R1193-203. doi: 10.1152/ajpregu.00256.2015. Epub 2015 Aug 26.
本文引用的文献
1
Pathophysiology and epidemiology of peripartum cardiomyopathy.围生期心肌病的病理生理学和流行病学。
Nat Rev Cardiol. 2014 Jun;11(6):364-70. doi: 10.1038/nrcardio.2014.37. Epub 2014 Apr 1.
2
MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.微小 RNA-146a 是围产期心肌病的治疗靶点和生物标志物。
J Clin Invest. 2013 May;123(5):2143-54. doi: 10.1172/JCI64365. Epub 2013 Apr 24.
3
Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.新型融合蛋白源自血管抑素 30 和血管生成素 II-14.1，能有效抑制冠状动脉内皮细胞增殖。
Mol Biotechnol. 2013 Jul;54(3):920-9. doi: 10.1007/s12033-012-9642-4.
4
The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.抗血管生成 16K 催乳素通过抑制血管成熟来损害功能性肿瘤血管生成。
PLoS One. 2011;6(11):e27318. doi: 10.1371/journal.pone.0027318. Epub 2011 Nov 7.
5
Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy.催乳素和血管抑制素：糖尿病视网膜病变的内源性参与者。
IUBMB Life. 2011 Oct;63(10):806-10. doi: 10.1002/iub.518. Epub 2011 Sep 13.
6
High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins.高血清催乳素水平通过增加眼部血管抑制素来预防糖尿病性视网膜病变。
Diabetes. 2010 Dec;59(12):3192-7. doi: 10.2337/db10-0873. Epub 2010 Sep 7.
7
Peptide hormone regulation of angiogenesis.肽类激素对血管生成的调节。
Physiol Rev. 2009 Oct;89(4):1177-215. doi: 10.1152/physrev.00024.2009.
8
Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.采用16K人催乳素进行的抗血管生成脂质体基因治疗可有效抑制肿瘤生长。
Cancer Lett. 2009 Nov 1;284(2):222-8. doi: 10.1016/j.canlet.2009.04.030. Epub 2009 May 26.
9
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.组织蛋白酶D切割产生的16 kDa催乳素形式介导产后心肌病。
Cell. 2007 Feb 9;128(3):589-600. doi: 10.1016/j.cell.2006.12.036.
10
Vasoinhibins: endogenous regulators of angiogenesis and vascular function.血管抑制素：血管生成和血管功能的内源性调节因子。
Trends Endocrinol Metab. 2006 Oct;17(8):301-7. doi: 10.1016/j.tem.2006.08.002. Epub 2006 Aug 23.
Zotero 插件